Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dick C Chan

Showing results (11-20 of 176) with videos related to

Pageof 18
Sort By:
Current Opinion in Endocrinology, Diabetes, and Obesity|February 26, 2026
The future of triglyceride-regulating therapies and registriesGerald F Watts, Dick C Chan
Journal of the American College of Cardiology|May 2, 2020
Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot?Gerald F Watts, Dick C Chan
Current Opinion in Lipidology|April 30, 2020
Metabolism of lipoprotein(a): new findings, implications and outstanding issuesDick C Chan, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity|February 24, 2022
Microplastics, cardiometabolic risk, genetics and Alzheimer's diseaseGerald F Watts, Dick C Chan
Atherosclerosis|January 17, 2013
PANACEA or much a do about nothing: effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndromeDick C Chan, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity|February 27, 2024
Addressing genetic and environmental sources of cardiometabolic diseaseGerald F Watts, Dick C Chan
Clinical and Translational Medicine|November 27, 2023
RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I studyGerald F Watts, Dick C Chan
Current Atherosclerosis Reports|November 20, 2024
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular DiseaseDick C Chan, Gerald F Watts
Current Opinion in Lipidology|February 19, 2024
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?Dick C Chan, Gerald F Watts
Clinical Therapeutics|July 31, 2023
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing TherapiesDick C Chan, Gerald F Watts
Pageof 18

Showing results (11-20 of 176) with videos related to

Sort By:
Pageof 18
Current Opinion in Endocrinology, Diabetes, and Obesity|February 26, 2026
The future of triglyceride-regulating therapies and registriesGerald F Watts, Dick C Chan
Journal of the American College of Cardiology|May 2, 2020
Atherogenic Dyslipoproteinemia and Management of ASCVD: Will New Indices Untie the Gordian Knot?Gerald F Watts, Dick C Chan
Current Opinion in Lipidology|April 30, 2020
Metabolism of lipoprotein(a): new findings, implications and outstanding issuesDick C Chan, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity|February 24, 2022
Microplastics, cardiometabolic risk, genetics and Alzheimer's diseaseGerald F Watts, Dick C Chan
Atherosclerosis|January 17, 2013
PANACEA or much a do about nothing: effect of a statin and ezetimibe on postprandial lipaemia and endothelial function in the metabolic syndromeDick C Chan, Gerald F Watts
Current Opinion in Endocrinology, Diabetes, and Obesity|February 27, 2024
Addressing genetic and environmental sources of cardiometabolic diseaseGerald F Watts, Dick C Chan
Clinical and Translational Medicine|November 27, 2023
RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: Findings and implications of a recent phase I studyGerald F Watts, Dick C Chan
Current Atherosclerosis Reports|November 20, 2024
Inhibition of the ANGPTL3/8 Complex for the Prevention and Treatment of Atherosclerotic Cardiovascular DiseaseDick C Chan, Gerald F Watts
Current Opinion in Lipidology|February 19, 2024
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?Dick C Chan, Gerald F Watts
Clinical Therapeutics|July 31, 2023
The Promise of PCSK9 and Lipoprotein(a) as Targets for Gene Silencing TherapiesDick C Chan, Gerald F Watts
Pageof 18